Intel Corporation vs Pfizer Inc.: Strategic Comparison
Key Differences at a Glance
| Field | Intel Corporation | Pfizer Inc. |
|---|---|---|
| Revenue | $52.9B | $62.6B |
| Founded | 1968 | 1849 |
| Employees | 85,100 | 75,000 |
| Market Cap | $536.6B | $148.0B |
| Headquarters | United States | United States |
Quick Stats Comparison
| Metric | Intel Corporation | Pfizer Inc. |
|---|---|---|
| Revenue | $52.9B | $62.6B |
| Founded | 1968 | 1849 |
| Headquarters | Santa Clara, California | New York, New York |
| Market Cap | $536.6B | $148.0B |
| Employees | 85,100 | 75,000 |
Intel Corporation Revenue vs Pfizer Inc. Revenue — Year by Year
| Year | Intel Corporation | Pfizer Inc. | Leader |
|---|---|---|---|
| 2025 | $52.9B | $62.6B | Pfizer Inc. |
| 2024 | $53.1B | $63.6B | Pfizer Inc. |
| 2023 | $54.2B | $59.6B | Pfizer Inc. |
| 2022 | $63.1B | $101.2B | Pfizer Inc. |
| 2021 | $79.0B | $81.3B | Pfizer Inc. |
Business Model Breakdown
Overview: Intel Corporation vs Pfizer Inc.
This in-depth comparison examines Intel Corporation and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Intel Corporation on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Intel Corporation and Pfizer Inc. is widest.
On the headline numbers, Intel Corporation reports annual revenue of $52.9B against $62.6B for Pfizer Inc., while their respective market capitalizations stand at $536.6B and $148.0B. Intel Corporation is headquartered in United States and Pfizer Inc. operates from United States, and those different home markets shape how each company competes.
Intel Corporation: Intel is no longer just a PC chip company. It is a turnaround story at the intersection of semiconductor design, national manufacturing strategy, data-center competition, and AI infrastructure.
Pfizer Inc.: Pfizer has repeatedly reinvented itself around new therapeutic waves, from industrial fermentation and penicillin to Lipitor, vaccines, COVID products, and now oncology. The 2025 profile is not a pandemic windfall story; it is a large pharmaceutical company trying to rebuild a durable growth base.
Business Models: How Intel Corporation and Pfizer Inc. Make Money
Intel Corporation and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Intel Corporation and Pfizer Inc..
Intel Corporation business model: Intel earns revenue from Client Computing Group, Data Center and AI, Network and Edge, Mobileye, and Intel Foundry. The model is capital intensive because Intel owns fabs, develops process nodes, and must fund both product design and manufacturing technology.
Pfizer Inc. business model: Pfizer makes money from patented prescription medicines, vaccines, oncology products, hospital therapies, rare disease products, collaborations, and global commercial distribution. Its economics depend on R&D success, regulatory approvals, patent protection, reimbursement, and lifecycle management.
Competitive Advantage: Intel Corporation vs Pfizer Inc.
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Intel Corporation stack up against those of Pfizer Inc..
Intel Corporation competitive advantage: Intel's advantage is still its x86 ecosystem, deep enterprise relationships, installed base, advanced packaging, U.S. manufacturing footprint, and potential strategic value as a geographically diversified foundry.
Pfizer Inc. competitive advantage: Pfizer advantage is scale: global regulatory expertise, manufacturing capacity, clinical development experience, commercial infrastructure, vaccine capabilities, and the ability to acquire or partner for scientific platforms.
Growth Strategy: Where Intel Corporation and Pfizer Inc. Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Intel Corporation and Pfizer Inc. each plan to expand from here.
Intel Corporation growth strategy: Intel is trying to restore product leadership, ramp advanced process nodes, win foundry customers, improve cost discipline, expand advanced packaging, and focus the portfolio under Lip-Bu Tan.
Pfizer Inc. growth strategy: Pfizer growth strategy emphasizes oncology, vaccines, internal medicine, obesity and metabolic research, business development discipline, cost reduction, and global commercial execution. Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.
Financial Picture: Intel Corporation vs Pfizer Inc.
A closer look at the financial trajectory of Intel Corporation and Pfizer Inc. rounds out the comparison.
Intel Corporation: Intel reported $52.853B in 2025 revenue and a $267M net loss attributable to Intel. Revenue was roughly flat, but profitability improved sharply from the 2024 restructuring-heavy loss.
Pfizer Inc.: Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.
Company-Specific SWOT Notes
Intel Corporation
Intel Corporation's main strength is Intel's advantage is its x86 installed base, manufacturing know-how, enterprise relationships, packaging technology, and strategic importance to domestic chip supply.
Intel Corporation has $52.
Intel Corporation's main watchpoint is Major exposures are foundry execution, AI accelerator competition, capital intensity, margin pressure, and share loss to AMD and ARM-based designs.
Intel Corporation's model depends on continued execution in semiconductors and can be pressured by pricing, regulation, capital intensity, or customer demand shifts.
Intel Corporation's current growth strategy is: Intel is trying to rebuild process leadership, scale Intel Foundry, simplify operations, and compete in AI PCs, servers, accelerators, and advanced packaging.
Intel Corporation competes with Advanced Micro Devices, Inc.
Pfizer Inc.
Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.
Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.
The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.
Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Pfizer Inc. | Pfizer Inc. reports the larger revenue base ($62.6B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Pfizer Inc. | Founded in 1968 vs 1849. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Intel Corporation | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Intel Corporation | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Intel Corporation | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Pfizer Inc. reports the larger revenue base ($62.6B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1968 vs 1849. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Intel Corporation or Pfizer Inc.?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Intel Corporation vs Pfizer Inc.
Is Intel Corporation better than Pfizer Inc.?
Verdict: Between Intel Corporation and Pfizer Inc., Pfizer Inc. is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Pfizer Inc. comes out ahead in this Intel Corporation vs Pfizer Inc. comparison.
Who earns more — Intel Corporation or Pfizer Inc.?
Pfizer Inc. earns more with $62.6B in annual revenue versus Intel Corporation's $52.9B. Pfizer Inc. leads on total revenue based on latest verified figures.
Which company has higher revenue — Intel Corporation or Pfizer Inc.?
Intel Corporation reported $52.9B, while Pfizer Inc. reported $62.6B. The revenue leader is Pfizer Inc. based on latest verified figures.
Intel Corporation revenue vs Pfizer Inc. revenue — which is higher?
Intel Corporation revenue: $52.9B. Pfizer Inc. revenue: $52.9B. Pfizer Inc. has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Intel Corporation Annual Filings (10-K, 8-K)
- Intel Corporation Corporate Website
- Intel Corporation Annual Report 2025 - Revenue and Financial Data
- sec.gov
- sec.gov
- sec.gov
- intc
- intel.com
- intel.com
- intel.com
- newsroom.intel.com
- data.sec.gov
- sec.gov
- data.sec.gov
- intel.com
- finance.yahoo.com
- SEC EDGAR: Pfizer Inc. Annual Filings (10-K, 8-K)
- Pfizer Inc. Corporate Website
- Pfizer Inc. Annual Report 2025 - Revenue and Financial Data
- sec.gov
- investors.pfizer.com
- pfizer.com
- investors.pfizer.com